Share on StockTwits

GTx (NASDAQ:GTXI) issued its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02, Analyst Ratings News reports. During the same quarter in the previous year, the company posted ($0.20) earnings per share.

GTx (NASDAQ:GTXI) traded down 0.14% during mid-day trading on Thursday, hitting $1.478. 124,770 shares of the company’s stock traded hands. GTx has a one year low of $1.26 and a one year high of $7.24. The stock’s 50-day moving average is $1.50 and its 200-day moving average is $1.6. The company’s market cap is $111.1 million.

GTx, Inc is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (NASDAQ:GTXI) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.